Background: Despite its common occurrence, the influence of malignant pleural effusion (MPE) on the outcomes of patients with advanced non-small-cell lung cancer (NSCLC) with distant metastasis (M1b) is unknown. We evaluated the clinical characteristics associated with MPE at presentation and the prognostic impact of MPE at presentation in patients with stage M1b NSCLC. Methods: We extracted data from the Surveillance Epidemiology and End Results (SEER) registry from patients with NSCLC diagnosed between 2004 and 2005. Odds-ratio estimates were calculated using logistic regression, and the Kaplan-Meier method was used to estimate the overall survival. Cox proportional hazard model was used to evaluate whether MPE was an independent risk for outcome. Results: Among the 57,685 patients, MPE was present in 9170 (15.9%), including 3944 out of 31,506 (12.5%) without distant metastases and 5226 (20.0%) out of 26,179 with M1b. The probability of MPE was higher in patients with larger tumors, mediastinal lymph node involvement, and adenocarcinoma, NSCLC not otherwise specified, or large-cell histology. In patients with stage M1b, median overall survival (3 months versus 5 months), estimated 1-year survival (12.6% versus 24.8%), and 2-year survival (5.4% versus 11.3%) were significantly lower in patients with MPE compared with those without MPE (hazards ratio 1.49, 95% confidence interval 1.44-1.54, p < 0.0001). MPE was also an independent factor for worse survival in multivariate analysis (hazards ratio 1.36, 95% confidence interval1.30-1.43, p < 0.001). Conclusions: MPE is a common complication in patients with NSCLC and is associated with decreased survival in patients with distant metastases. If these data are validated, subsequent studies in patients with advanced NSCLC may consider stratification according to the MPE status.
M alignant pleural effusion (MPE), defined by the presence of malignant cells in the pleural space, indicates advanced disease, and is associated with significant morbidity. 1 MPE is a common complication of malignancies, with an estimated incidence of more than 150,000 cases annually. 2 Although any malignancy may involve the pleura, the most common causes for MPE are lung cancer (37.5%), breast cancer (16.8%), and lymphoma (11.5%). 3 It is estimated that 8% to 15% of patients with lung cancer have MPE. 4, 5 Because of the significantly inferior overall survival (OS) compared with other patients with T4 disease, according to previous stage classifications, MPE was moved from the T4 (stage IIIB) to M1a (stage IV) category in the 7th edition of the Tumor Node Metastasis classification. 6, 7 Moreover, the treatment of patients with MPE without distant metastases is the same (chemotherapy) as that for patients with non-smallcell lung cancer (NSCLC) and distant metastases.
Despite the common occurrence of MPE, most studies evaluating its epidemiology and demographic characteristics are small, retrospective, and were conducted decades ago. In addition, although MPE is a known poor prognostic factor in patients without metastatic disease, it remains unknown whether the presence of MPE is associated with worse outcomes in patients with distant disease (M1b). We conducted a Surveillance, Epidemiology and End Results (SEER) survey to evaluate the characteristics of patients with MPE because of NSCLC and its prognostic impact in patients with stage M1b disease.
METHODS
We searched the SEER-17 registry data for patients with non-small cell lung cancer, aged 21 years or older, with active follow-up, and diagnosed between 2004 and 2005. MPE was defined as collaborative stage extension code 72. The histology was coded according to the International Classification of Diseases for Oncology (ICD-0-3) into adenocarcinoma (8140-8147, 8255, 8260, 8310, 8323, 8480, 8481, 8490, 8550,(8013) , and other histologies, including undifferentiated tumors (8020-8022) and carcinomas not otherwise specified (NOS) (8010). Demographic variables were defined as age at diagnosis, sex, race, histology, tumor size, tumor status (T), and lymph node status (N). Age groups were subdivided into 21 to 60 years, 61 to 70 years, 71 to 80 years, and older than 80 years. Tumor size was subdivided into 0 to 3 cm, 3.1 to 5 cm, 5.1 to 7 cm, and 7.1 to 20 cm to match the new American Joint Committee on Cancer staging for T1, T2a, T2b, and T3.
Statistical Analysis
Odds ratios (OR) were calculated by logistic regression. OS, defined as time from diagnosis to death from any cause, was estimated using the Kaplan-Meier product method and compared by the log-rank test. Cox proportional hazards models were used to find hazard ratios adjusted for demographic and clinical covariates. All statistical tests were two-sided and p values less than 0.05 were considered to be significant. Statistical analyses were performed using SAS (version 9.1; SAS Institute, Cary, NC).
RESULTS

Demographics
The cohort was composed of 57,685 patients who met the inclusion criteria ( There were 26,179 patients with distant disease (M1b) included in the survival analysis. Several demographic factors influenced the survival for patients with M1b in both univariate and multivariate analyses (Table 4) . Predictors for poor outcomes were advanced age, male sex, black race, advanced T and N stage, large tumor size, and histologies other than adenocarcinoma or BAC. MPE was associated with decreased median OS (3 months versus 5 months), estimated 1-year survival (12.6% versus 24.8%), and 2-year survival (5.4% versus 11.3%) compared with those without MPE (HR 1.49, 95% CI 1.44-1.54, p < 0.001) (Fig. 1) . MPE was also an independent factor for worse survival in multivariate analysis (HR 1.36, 95% CI 1.30-1.43, p < 0.001).
DISCUSSION
The influx and exit of pleural space fluids and proteins are balanced to keep a constant volume in normal state. Both the fluid and proteins leave the pleural space through the parietal pleura stomata, which are 2-to 12-µm openings between mesothelial cells and communicate directly to the lymphatic lacunae, which in turn converge into collecting lymphatics that drain into lymphatic channels along the ribs and subsequently to the mediastinal lymph nodes. 8 MPE occurs mostly because of impaired lymphatic drainage, anywhere from tumor occlusion of the parietal pleura stomata to enlarged mediastinal lymph nodes. In patients with lung cancer, MPEs are usually caused by pulmonary artery invasion and embolization of tumor cells to the visceral pleura or direct invasion from peripheral tumors. 9 Meyer et al. 10 found a significant relation between mediastinal lymph node involvement and the development of MPE, whereas there was no correlation with the extent of pleural involvement by nodular metastases. Our study confirmed the importance of mediastinal lymph node involvement in the development of MPE, with an increased frequency of MPE from 10.2% to 11.4% to in patients with N0/N1 involvement to 18% to 20% in those with N2/N3 disease (p < 0.001).
Among NSCLC histologies, adenocarcinoma seems to be the most commonly associated with MPE. Irani et al. 11 reviewed 620 pleural cytology specimens from 1978 to 1982, finding 61 (9.8%) positive for MPE. Among the positive cytologies, lung adenocarcinoma was the most common histology with 25 patients (41%). Similarly, Chernow and Sahn 12 found adenocarcinoma histology in 18 of 32 patients (56%) with lung cancer. Our study confirmed the increased association between adenocarcinoma and MPE, which may be related to the usual peripheral location with possible higher rates of local extension into the pleura. To further support this finding, the probability of MPE was also higher in large-cell histology, which also presents more commonly as a peripheral lesion, whereas it was lower in the typically centrally located squamous cell carcinoma. Nevertheless, it should be noted that 27% of the patients were diagnosed with NSCLC NOS. This lack of adequate histological definition has been described in a recent SEER analysis, in which the percentage of patients diagnosed with NOS histology increased from 15.8% in the 1989-1994 period to 22% and 29% in the 1995-2000 and 2000-2006 periods, respectively, being more common in elderly and stage IV patients diagnosed cytologically. 13 In our study, the probability of MPE increased with each tumor size category, increasing significantly from 7.5% in patients with tumors between 0 and 3 cm to 17.2% in those with tumors larger than 7 cm.
The International Association for the Study of Lung Cancer (IASLC) staging study showed a significantly lower median and 5-year OS rates for patients with MPE (8 months, 2%) compared with those with same-lobe nodules (28 months, 
